Clostridium difficile 027 infection in Central Italy

BMC Infectious Diseases

Nicola Petrosillo²  Emma Johnson¹  Maria Grazia Paglia²  Stefano Di Bella² 

[1] Medical Microbiology Registrar, Department of Microbiology, Northern General Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, South Yorkshire, UK;National Institute for Infectious Diseases “L. Spallanzani”, Via Portuense 292, Rome, 00149, Italy

关键词: Italy;    027;    NAP1;    CDAD;    Clostridium difficile;   

Others  :  1158659
DOI  :  10.1186/1471-2334-12-370

 received in 2012-06-19, accepted in 2012-12-20,  发布年份 2012

【 摘 要 】

Background

Clostridium difficile (CD) has increasingly become recognised as a significant international health burden, often associated with the healthcare environment. The upsurge in incidence of CD coincided with the emergence of a hypervirulent strain of CD characterized as 027.

In 2010, 8 cases of CD 027 infections were identified in Italy. Since then, no further reports have been published. We describe 10 new cases of CD 027 infection occurring in Italy.

Methods

Since December 2010, stool samples of patients with severe diarrhea and clinical suspicion of the presence of a hypervirulent strain, were tested for CD 027 by the Xpert C. difficile PCR assay (Cepheid, Sunnyvale, CA). Clinical, epidemiological and laboratory data were collected.

Results

From December 2010 to April 2012, 24 faecal samples from 19 patients who fit the above criteria were submitted to our laboratory. Samples were collected from 7 different hospitals.

Of these, 17 had a positive PCR for CD and 10 were the epidemic 027 strain (59%). All PCR positive samples had a positive EIA toxin A/B test. Nine of 10 patients were recently exposed to antimicrobials and were healthcare-associated, including 4 with a history of long term care facility (LTCF) admission; the remaining case was community-associated, namely the wife of a patient with hospital-acquired CD 027 infection. Five patients experienced at least one recurrence of CD associated diarrhea (CDAD) with a total of 12 relapsing episodes. Of these, two patients had 5 and 6 relapses respectively.

We compared the 10 patients with 027 CDAD versus the 7 patients with non-027 CDAD. None of the 7 patients with non-027 CDAD had a recent history of LTCF admission and no subsequent relapses were observed (p = 0.04).

Conclusions

Our study shows that CD 027 is emerging in healthcare facilities in Italy. Whilst nosocomial acquisition accounted for the majority of such cases, 4 patients had history of a recent stay in a LTCF. We highlight the substantial risks of this highly transmissible organism in such environments. Moreover, 50% of our patients with CDAD from the 027 strain had high relapse rates which may serve to further establish this strain within the Italian health and social care systems.

【 授权许可】

   
2012 Di Bella et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Bartlett JG, Gerding DN: Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 2008, 46(Suppl 1):S12-S18.
• [2]Kelly CP, LaMont JT: Clostridium difficile—more difficult than ever. N Engl J Med 2008, 359:1932-1940.
• [3]Kachrimanidou M, Malisiovas N: Clostridium difficile infection: a comprehensive review. Crit Rev Microbiol 2011, 37:178-187.
• [4]Kuijper EJ, Coignard B, Tüll P, ESCMID Study Group for Clostridium difficile EU Member States; European Centre for Disease Prevention and Control: Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006, 12(Suppl 6):2-18.
• [5]Pépin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, Pépin K, Chouinard D: Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. Can Med Assoc J 2004, 171:466-472.
• [6]Office for National Statistics: Deaths involving Clostridium difficile: England and Wales, 1999 and 2001–06. Health Stat Q 2008, 37:52-56.
• [7]McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, Johnson S, Gerding DN: An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005, 353:2433-2441.
• [8]Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn S, Dewar K, Hudson TJ, Horn R, René P, Monczak Y, Dascal A: A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005, 353:2442-2449.
• [9]Smith A: Outbreak of Clostridium difficile infection in an English hospital linked to hypertoxin-producing strains in Canada and the US. Euro Surveill 2005, 10:E050630.2.
• [10]Kim H, Lee Y, Moon HW, Lim CS, Lee K, Chong Y: Emergence of Clostridium difficile ribotype 027 in Korea. Korean J Lab Med 2011, 31:191-196.
• [11]Miller M, Gravel D, Mulvey M, Taylor G, Boyd D, Simor A, Gardam M, McGeer A, Hutchinson J, Moore D, Kelly S: Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 2010, 50:194-201.
• [12]Labbé AC, Poirier L, Maccannell D, Louie T, Savoie M, Béliveau C, Laverdière M, Pépin J: Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. Antimicrob Agents Chemother 2008, 52:3180-3187.
• [13]Barbut F, Mastrantonio P, Delmée M, Brazier J, Kuijper E, Poxton I, European Study Group on Clostridium difficile (ESGCD): Prospective study of Clostridium difficile infections in Europe with phenotypic genotypic characterization of the isolates. Clin Microbiol Infect 2007, 13:1048-1057.
• [14]Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC: Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005, 366:1079-1084.
• [15]Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N, Toye B, Beaudoin A, Frost EH, Gilca R, Brassard P, Dendukuri N, Béliveau C, Oughton M, Brukner I, Dascal A: Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011, 365:1693-1703.
• [16]Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, Monnet DL, van Dissel JT, Kuijper EJ, ECDIS Study Group: Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011, 377:63-73.
• [17]Spigaglia P, Barbanti F, Dionisi AM, Mastrantonio P: Clostridium difficile isolates resistant to fluoroquinolones in Italy: emergence of PCR ribotype 018. J Clin Microbiol 2010, 48:2892-2896.
• [18]Baldan R, Cavallerio P, Tuscano A, Parlato C, Fossati L, Moro M, Serra R, Cirillo DM: First report of hypervirulent strain polymerase chain reaction ribotypes 027 and 078 causing severe Clostridium difficile infection in Italy. Clin Infect Dis 2010, 50:126-127.
• [19]Babady NE, Stiles J, Ruggiero P, Khosa P, Huang D, Shuptar S, Kamboj M, Kiehn TE: Evaluation of the Cepheid Xpert Clostridium difficile Epi assay for diagnosis of Clostridium difficile infection and typing of the NAP1 strain at a cancer hospital. J Clin Microbiol 2010, 48:4519-4524.
• [20]Bauer MP, Kuijper EJ, van Dissel JT, European Society of Clinical Microbiology and Infectious Diseases: European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009, 15:1067-1079.
• [21]Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH, Society for Healthcare Epidemiology of America; Infectious Diseases Society of America: Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31:431-455.
• [22]Aslam S, Hamill RJ, Musher DM: Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005, 5:549-557.
• [23]Pepin J, Alary ME, Valiquette L, Raiche E, Ruel J, Fulop K, Godin D, Bourassa C: Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec. Canada. Clin Infect Dis 2005, 40:1591-1597.
• [24]Huang H, Weintraub A, Fang H, Nord CE: Community acquired Clostridium difficile infection due to a moxifloxacin susceptible ribotype 027 strain. Scand J Infect Dis 2009, 41:158-159.
• [25]Rodemann JF, Dubberke ER, Reske KA, Seo da H, Stone CD: Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007, 5:339-344.
• [26]Ananthakrishnan AN, McGinley EL, Binion DG: Excess of hospitalization burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008, 57:205-210.
• [27]Issa M, Vijayapal A, Graham MB, Beaulieu DB, Otterson MF, Lundeen S, Skaros S, Weber LR, Komorowski RA, Knox JF, Emmons J, Bajaj JS, Binion DG: Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007, 5:345-351.
• [28]Stange EF, Travis SP, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, Feakins R, Fléjou JF, Herfarth H, Hommes DW, Kupcinskas L, Lakatos PL, Mantzaris GJ, Schreiber S, Villanacci V, Warren BF, for the European Crohn’s and Colitis Organisation (ECCO): European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis 2008, 2:1-23.
• [29]Kyne L, Warny M, Qamar A, Kelly CP: Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhea. Lancet 2001, 357:189-193.
• [30]Warny M, Vaerman JP, Avesani V, Delmée M: Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 1994, 62:384-389.
• [31]Riggs MM, Sethi AK, Zabarsky TF, Eckstein EC, Jump RL, Donskey CJ: Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 2007, 45:992-998.
• [32]Simor AE, Bradley SF, Strausbaugh LJ, Crossley K, Nicolle LE, SHEA Long-Term-Care Committee: Clostridium difficile in long-term-care facilities for the elderly. Infect Control Hosp Epidemiol 2002, 23:696-703.
• [33]Goorhuis A, Van der Kooi T, Vaessen N, Dekker FW, Van den Berg R, Harmanus C, van den Hof S, Notermans DW, Kuijper EJ: Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in The Netherlands. Clin Infect Dis 2007, 45:695-703.
• [34]Petrella LA, Sambol SP, Cheknis A, Nagaro K, Kean Y, Sears PS, Babakhani F, Johnson S, Gerding DN: Decreased cure and increased recurrence rate for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis 2012, 55:351-7.